Pola-ZR2P for untreated DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- At least 18 years old.
- Have not received chemotherapy before for any condition.
- Expected to live at least 3 more months.
- No active infections needing treatment in the last 2 weeks.
- No serious heart, liver, kidney, or other organ problems.
- Not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This study looks at how well a drug called polatuzumab works for people with a type of lymphoma (DLBCL) in everyday medical practice in China. It is for patients who are older, have other health problems, or whose lymphoma came back after or did not respond to treatment.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a new combination of drugs (Pola-ZR2) against a standard combination (ZR2) for older adults with newly diagnosed diffuse large B-cell lymphoma. It aims to see if the new mix is more effective and safe.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs (G-Pola-ZLP) for people with newly diagnosed Diffuse Large B-Cell Lymphoma who have not had chemotherapy before. The goal is to see if this treatment works well and is safe.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.